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Abstract
Background: The derivative of caffeamide exhibits antioxidant and antityrosinase activity. The activity and mechanism
of N-(4-methoxyphenyl) caffeamide (K36E) on melanogenesis was investigated.
Methods: B16F0 cells were treated with various concentrations of K36E; the melanin contents and related
signal transduction were studied. Western blotting assay was applied to determine the protein expression,
and spectrophotometry was performed to identify the tyrosinase activity and melanin content.
Results: Our results indicated that K36E reduced α-melanocyte-stimulating hormone (α-MSH)-induced melanin
content and tyrosinase activity in B16F0 cells. In addition, K36E inhibited the expression of phospho-cyclic adenosine
monophosphate (cAMP)-response element-binding protein, microphthalmia-associated transcription factor (MITF),
tyrosinase, and tyrosinase-related protein-1 (TRP-1). K36E activated the phosphorylation of protein kinase B (AKT) and
glycogen synthase kinase 3 beta (GSK3β), leading to the inhibition of MITF transcription activity. K36E attenuated
α-MSH induced cAMP pathways, contributing to hypopigmentation.
Conclusions: K36E regulated melanin synthesis through reducing the expression of downstream proteins
including p-CREB, p-AKT, p-GSK3β, tyrosinase, and TRP-1, and activated the transcription factor, MITF. K36E may have
the potential to be developed as a skin whitening agent.
Keywords: N-(4-methoxyphenyl) caffeamide, Melanogenesis, Propolis, Microphthalmia-associated transcription factor,
cAMP response element-binding protein, Glycogen synthase kinase 3 beta
Background
Melanin plays a pivotal role in preventing photodamage
and photocarcinogenesis of the skin; however, abnormal
accumulation of melanin induces hyperpigmentation
disorders such as age spots and melasma [1, 2]. Melano-
genesis is a series of complex process with many partici-
pating factors. Genetic background is the most crucial
factor for skin pigmentation; more than 150 genes have
been found to regulate melanin biosynthesis [3–5]. More-
over, nongenetic factors, such as medication, hormonal
changes, inflammation, ageing, and exposure to ultraviolet
(UV) irradiation, affect skin pigmentation [4, 5]. Melano-
genesis is regulated by various proteins and enzymes including
tyrosinase, microphthalmia-associated transcription factor
(MITF), tyrosinase-related protein-1 (TRP-1), and tyrosinase-
related protein-2 (TRP-2) [4, 6–8]. UV irradiation stimulates
the secretion of α-melanocyte-stimulating hormone (α-MSH)
in keratinocytes, which binds to the melanocortin 1 receptor
(MC1R) and catalyses adenosine triphosphate conversion to
cyclic adenosine monophosphate (cAMP) [9]. cAMP stimu-
lates protein kinase A (PKA), and PKA translocates into the
nucleus and activates cAMP-response element-binding pro-
tein (CREB) [10, 11]. Phospho-cAMP-response element bind-
ing protein (p-CREB) increases the expression of MITF to
induce the expression of tyrosinase, TRP-1, and TRP-2. Tyro-
sinase undergoes maturation and activation through multiple
mechanisms, including copper binding, glycosylation, and
phosphorylation, resulting inmelanin synthesis [12].
Substantial research has studied the regulation of melanin
biosynthesis for the development of hypopigmenting
agents. To inhibit tyrosinase activity and reduce melanin
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synthesis, several tyrosinase inhibitors that prevent
hyperpigmenation have been developed through either
synthesis or isolation from natural sources [1, 2, 7, 13].
N-(4-methoxyphenyl) caffeamide (K36E; Fig. 1) is an
analogue of caffeic acid phenethyl ester, an active com-
ponent of propolis. In our previous study, a caffeamide
derivative exhibited antioxidant properties, prevented
the degradation of skin collagen after UVB exposure,
and stimulated collagen synthesis in human skin fibro-
blasts and in hairless mice [14, 15]. Another caffeamide
derivative exhibited antimelanogenic activity by inhibiting
tyrosinase activity and expression [16]. Moreover, caffeic
acid derivatives such as trans-N-caffeoyltyramine and
trans-N-dihydro-p-hydroxycinnamoyltyramine inhibited
tyrosinase activity in melanocytes [17]. Thus, we specu-
lated that K36E inhibits melanogenesis. In the current
study, we investigated the effect of K36E activity on
melanin synthesis in B16F0 cells, which is a well-estab-
lished model for the investigation of skin whitening agents
[18–20]. In addition, we investigated whether the antimela-
nogenic activity of K36E depends on the regulation of TRP-




K36E was synthesized and identified by Professor Yueh-
Hsiung Kuo with a purity of 99.9% [21]. α-MSH was
purchased from Merck (Darmstadt, Germany). Arbutin,
3,4-dihydroxy-L-phenylalanine (L-DOPA), DL-dithiothreitol,
H-89 dihydrochloride hydrate, phenylmethanesulfonyl
fluoride, and L-tyrosine were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO, USA). Fetal bovine
serum (FBS), Dulbecco’s modified Eagle’s medium (DMEM)
and trypsin- ethylenediaminetetraacetic acid (EDTA) were
purchased from the GIBCO Invitrogen Corporation
(NY, USA). An antibody recognising MITF was obtained
from Abcam (Cambridge, MA, USA). Antibodies recognis-
ing p-CREB and CREB were purchased from Cell Signalling
Technology, Inc. (Danvers, MA, USA). Antibodies recog-
nising phospho-AKT, AKT, and phospho-glycogen synthase
kinase 3 beta (p-GSK3β) were obtained from GeneTex,
Inc. (CA, USA). Antibodies recognising actin, GSK3β,
TRP-1, and tyrosinase were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA).
Effect of K36E on mushroom tyrosinase inhibition
The activity of mushroom tyrosinase was spectrophotomet-
rically determined with minor modifications to the previ-
ously described procedure [7, 21–23]. Arbutin (2 mM) was
the positive control. The test sample and L-tyrosine in
phosphate buffer saline (PBS) and were added to a 96-
well microplate (Nunc, Denmark), and mushroom tyro-
sinase was added. After incubation, the amount of
dopachrome produced in the reaction mixture was
determined at the optical density of 492 nm by using a
microplate reader (Tecan, Grodig, Austria).
Cell cultures
B16F0 cells were purchased from the Bioresource Col-
lection and Research Centre in Taiwan and cultured in
DMEM supplemented with 10% FBS and 100 units/mL
of penicillin and streptomycin at 37 °C in 5% CO2.
Cell viability assay
Cell growth experiments were performed using a 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) assay with minor modifications to the previously
described procedure [7, 8, 24, 25]. Hydrogen peroxide was
used as the positive control. The cells were cultured over-
night and treated with various concentrations of K36E for
48 h, and an MTT solution was then added to each well.
After incubation, a sodium dodecyl sulphate (SDS) solu-
tion was added, dissolving the formazan crystals produced
in the cells. The optical density was measured at 570 nm
by using a microplate reader (Tecan, Grodig, Austria).
Cellular melanin content
The melanin content in B16F0 cells was measured by
using a method modified from previous studies [7, 8, 23].
The B16F0 cells were seeded in 6-well plates at a density
of 7 × 104 cells per well and incubated overnight. The cells
were exposed to a medium containing α-MSH and K36E
for 48 h. Arbutin (1 mM) was the positive control. NaOH
(2 N) was added to each well to lyse the cells, which were
then centrifuged. The melanin content in the supernatant
was measured at 405 nm by using an ELISA reader
(Tecan, Grodig, Austria).
Cellular tyrosinase activity assay
The tyrosinase activity of B16F0 cells after K36E treatment
was measured with slight modification on the method de-
scribed in previous studies [7, 26, 27]. B16F0 cells were
plated in 24-well multidishes and incubated overnight.






Fig. 1 Structure of K36E
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K36E and were incubated for another 48 h. They were
washed with PBS and lysed with 1% Triton X-100 mixed
in 100 mM PBS (pH 6.8); the resultant mixture was frozen
during incubation at −80 °C for 15 min and thawed at
room temperature. Subsequently, the samples were centri-
fuged. A freshly prepared substrate (15 mM L-DOPA in a
48 mM pH 7.1 sodium phosphate buffer) was added to
the supernatant and incubated. The absorbance was
subsequently measured at 405 nm by using a micro-
plate reader (Tecan, Grodig, Austria).
The rate of tyrosinase activity was calculated using the
following equation:




Western blot analysis was used to demonstrate the
effects of K36E on the expression of melanogenesis-
related proteins in B16F0 cells as previously described
[7, 8, 22, 28, 29]. B16F0 cells were seeded in a 10-cm
dish for 24 h and treated with α-MSH alone (control
group) or with α-MSH plus various concentrations of
K36E for 48 h. The lysates were centrifuged and the
protein content was determined using a Bradford reagent
(Bio-Rad, Hercules, CA, USA). Twenty micrograms of
protein were separated on a sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) gel and blot-
ted using a polyvinylidene difluoride (PVDF) membrane
(Hybond ECL, Amersham Pharmacia Biotech Inc.,
Piscataway, NJ, USA). The blots were blocked with
5% (w/v) skimmed milk in Tris-buffered saline con-
taining 0.05% Tween 20 and with specific antibodies:
actin (1:1000), AKT (1:5000), p-AKT (1:5000), CREB
(1:1000), p-CREB (1:1000), GSK3β (1:500), p-GSK3β
(1:500), MITF (1:1000), TRP-1 (1:500), and tyrosinase
(1:200). The PVDF membranes were incubated with
the corresponding conjugated anti-immunoglobulin
G horseradish peroxidase (Santa Cruz Biotechnology,
Inc.). Immunoreactive proteins were detected using
an Enhanced Chemiluminescence Plus kit (Fujifilm, LAS-
4000), and signal strengths were quantified using a
densitometric program (MultiGauge V2.2). The results
of western blot assays represented at least three individ-
ual experiments.
Statistical analyses
Values were expressed as the mean ± standard deviation
from the results of at least three individual experiments.
Differences in the effects of various treatments were
compared using the Student’s t-test or ANOVA as well
as Scheffe’s test through SPSS software (version 12.0).
P values <0.05 indicated significance.
Results
Inhibition of mushroom tyrosinase activity by K36E
K36E at 1000 μM significantly reduced the mushroom tyro-
sinase activity. The mushroom tyrosinase inhibitory effect
at 500, 750 and 1000 μM was 6.8% ± 1.6%, 14.0% ± 7.1%
and 36.8% ± 1.1%, respectively. In addition, the inhibition
rate of 2 mM arbutin on mushroom tyrosinase activity was
65.3% ± 2.5%.
Effect of K36E on the viability of B16F0 cells
Cell viability after treatment with 1, 1.5, 2, 2.5, 4, 5, 10,
25, and 50 μM K36E was 92.7% ± 2.0%, 91.7% ± 2.1%,
90.9% ± 2.2%, 87.8% ± 4.2%, 72.8% ± 1.0%, 68.5% ± 2.4%,
54.6% ± 1.6%, 38.3% ± 0.8%, and 28.4% ± 2.3%, respect-
ively. Hydrogen peroxide was the positive control, and
the cell viability of 0.1 μM H2O2 was 48.9% ± 7.5% after
48 h treatment. The cell viability was acceptable for
developing a material for cosmetics. According to Inter-
national Organization for Standardization (ISO) 10993–
5:2009 (Biological Evaluation of Medical Devices), cell
viability higher than 80% is considered as noncytotoxicity.
The results indicated that treatment with 0.5 to 2.5 μM
K36E for 48 h had no cytotoxic effect on the B16F0 cells.
Inhibition of melanin biosynthesis by K36E in B16F0 cells
Figure 2a shows the effects of K36E on melanin bio-
synthesis after stimulation by 0.5 μM α-MSH in B16F0
Fig. 2 Effects of K36E on melanogenesis of B16F0 cells. a K36E reduced
α-MSH-induced melanin content (%) of B16F0 cells. (Significant difference
vs. control: ###, P < 0.001; significant difference vs. α-MSH-treated
group: **, P< 0.01; ***, P< 0.001) and (b) tyrosinase activity (%) of B16F0
cells treated with K36E. (Significant difference vs. control: ***, P< 0.001)
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cells. The intracellular melanin content increased to
124.6% ± 13.0% after treatment with α-MSH. K36E at
doses higher than 1.0 μM significantly reduced the
melanin content, which decreased to 97.5% ± 1.9%,
96.6% ± 3.3%, 94.4% ± 2.8%, and 90.8% ± 1.4% (Fig. 2a).
The effect of K36E on melanin biosynthesis was similar
to that of 1 mM of arbutin.
Inhibition of tyrosinase activity by K36E in B16F0 cells
K36E significantly inhibited tyrosinase activity in B16F0
cells after treatment for 48 h (Fig. 2b). The levels of tyro-
sinase activity were 83.2% ± 2.1%, 76.3% ± 2.9%, 72.0% ±
5.0%, and 67.2% ± 4.4% after treatment with 1, 1.5, 2,
and 2.5 μM K36E, respectively, for 48 h. The results in-
dicated that K36E inhibited the melanin content of
B16F0 cells through the inhibition of tyrosinase activity.
Effects of K36E on melanogenesis-related proteins
K36E downregulated tyrosinase and TRP-1 expression
To examine whether the inhibition of melanogenesis by
K36E was related to the expression levels of melanogenesis-
related proteins, including tyrosinase and TRP-1, B16F0 cells
were incubated with α-MSH (0.5 μM) and various concen-
trations of K36E (1–2.5 μM) for 48 h. Although tyrosinase
expression exhibited a 2.7-fold increase compared with
that in the control after treatment with α-MSH, K36E
significantly suppressed tyrosinase expression in a dose-
dependent manner (Fig. 3). In addition, K36E significantly
reduced α-MSH-stimulated TRP-1 expression at doses
higher than 1.5 μM (Fig. 3).
K36E downregulated MITF expression
MITF expression in B16F0 cells exhibited a 1.5-fold
increase compared with that in the control after treatment
with α-MSH (Fig. 4). K36E treated for 4 h dose-
dependently inhibited MITF expression and signifi-
cantly downregulated MITF expression in the B16F0
cells at a concentration of 1 μM (Fig. 4).
K36E downregulated p-CREB expression
p-CREB expression in B16F0 cells exhibited a 1.4-fold
increase compared with that in the control after α-MSH
treatment (Fig. 5). K36E significantly inhibited p-CREB
expression at concentrations higher than 1.5 μM and
subsequently downregulated MITF expression in the
B16F0 cells.
Effects of K36E on the melanogenesis signalling pathway
K36E-inhibited melanogenesis was associated with PKA
regulation
To determine whether K36E-inhibited melanogenesis was
associated with PKA, B16F0 cells were incubated with
10 μM H-89, a PKA inhibitor [30], and 2.5 μM K36E for
48 h. Treatment with K36E and H-89 separately caused a
1.2- and 1.5-fold decrease in α-MSH-induced tyrosinase
expression, respectively, compared with that in the control
(Fig. 6). In addition, cotreatment with K36E and H-89
cause a 0.9-fold decrease in tyrosinase expression com-
pared with that in the control. In addition, the tyrosinase
expression following cotreatment was significant lower
than that of K36E or H-89 treatment separately. The re-
sults indicated that the PKA pathway may be involved in
the antimelanogenic effect of K36E.
Fig. 3 Effect of K36E on α-MSH-induced expression of tyrosinase and
TRP-1 in B16F0 cells. (Significant difference vs. control: ###, P< 0.001;
significant difference vs. α-MSH-treated group: **, P< 0.01; ***, P< 0.001)
Fig. 4 Effect of K36E on α-MSH-induced expression of MITF in B16F0
cells. (Significant difference vs. control: ###, P < 0.001; significant
difference vs. α-MSH treated group: *, P < 0.05 ***, P < 0.001)
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K36E inhibited melanogenesis by upregulating p-AKT and
p-GSK3β expression
As shown in Fig. 7, treatment with 2.5 μM K36E for 1 h
markedly increased p-AKT and p-GSK3β expression.
The level of p-AKT reached a maximum (1.6-fold in-
crease compared with that in the control) after 1 h and
1.5-fold increase after 2 h; the level of p-GSK3β also dis-
played a 1.2-fold increase after 1 h compared with that
in the control, suggesting that K36E suppressed melano-
genesis in B16F0 cells by activating the AKT and GSK3β
signalling pathways, resulting in the inhibition of MITF
expression and transcription activity and, thus, inhibiting
the expression of the tyrosinase gene.
Discussion
Tyrosinase and its activity play a major role in control-
ling melanogenesis [31–33]. Agents or products that
inhibit tyrosinase activity have been used in skin whitening
cosmetics and cosmeceuticals [1, 2, 34]. Quercetin and
vanillic acid inhibited α-MSH induced the expression of
MITF, tyrosinase, TRP-1, and TRP-2, causing melano-
genesis inhibition [35, 36]. Resveratrol derivatives inhibited
melanin synthesis through the inhibition of melanogenic
enzyme expressions such as tyrosinase and TRP-1 [37].
Our results indicated that K36E inhibited tyrosinase activity
and α-MSH-induced protein expression, thereby sup-
pressing melanin biosynthesis. In addition, K36E inhib-
ited melanogenesis-related proteins such as TRP-1. TRP-1
is considered to play a vital role both as a structural pro-
tein and catalytic enzyme in the eumelanic pathway of
Fig. 5 Effect of K36E on α-MSH-induced expression of p-CREB in
B16F0 cells. (Significant difference vs. control: ###, P < 0.001; significant
difference vs. α-MSH-treated group: **, P < 0.005)
Fig. 6 Effect of K36E on α-MSH-induced expression of tyrosinase in
B16F0 cells after treatment with H-89. (Significant difference vs.
control: ###, P < 0.001; significant difference vs. α-MSH-treated
group: **, P < 0.01; ***, P < 0.001)
Fig. 7 Effect of K36E on expression of p-AKT and p-GSK3β in B16F0 cells.
(Significant difference vs. control: *, P< 0.05; **, P< 0.01; ***, P< 0.001)
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melanosomes [38, 39]. The results mentioned above sug-
gested that the decrease in melanogenesis of K36E could
be achieved through its inhibition on the signalling path-
way that regulates tyrosinase expression and activity.
MITF is the most critical transcription factor that
regulates melanogenesis by inducing the expression of
melanogenic genes [5, 40]. MITF activation upregulates
the expression of tyrosinase and TRP-1, and it conse-
quently increases melanin synthesis. In this study, K36E
suppressed melanogenesis by inhibiting α-MSH induced
MITF expression. The cAMP pathway plays a pivotal role
in α-MSH-induced melanogenesis. In previous study,
cAMP-elevating agents inhibited PI3K/AKT. GSK3β
may stimulate the binding of MITF to its target sequence
to stimulate the expression of melanogenic enzymes and
facilitate melanin production [41]. cAMP inhibits PI3K and
AKT phosphorylation and activity, and reduces GSK3β
phosphorylation to stimulate its activity. The activation of
cAMP signal transduction results in the binding of MITF
to the tyrosinase promoter, thereby leading to the stimulation
of melanogenesis [41, 42]. Activation of the AKT pathway
suppressed melanin synthesis by decreasing melanogenic en-
zymes [41]. Cordycepin was reported to inhibit α-MSH and
IBMX induced melanin biosynthesis by inhibiting melanin
synthesis related enzymes, such as tyrosinase, TRP-1, and
TRP-2, suppressing CREB and MITF activity, and activating
the PI3K/AKT pathway in B16F10 melanoma cells [43]. In
our results, K36E inhibited CREB phosphorylation. K36E ele-
vated the expression of p-AKT and p-GSK3β, possibly redu-
cing MITF transcription to suppress tyrosinase gene
expression. Previous studies have reported that the activation
of AKT inhibited melanogenesis in melanocytes [33, 44].
Thus, K36E inhibited α-MSH induced hyperpigmentation
caused by AKT and GSK3β activation, and subsequently
downregulated MITF, CREB, tyrosinase, and TRP-1 produc-
tion (Fig. 8).
UV exposure stimulates the secretion of α-MSH in
keratinocytes. α-MSH binds to MC1R in melanocytes,
resulting in cAMP production and PKA activation [10].
The signal transduction related to the cAMP pathway,
including the activation of PKA and CREB transcription
factors, leads to the upregulation of MITF [45]. PKA
subsequently phosphorylates CREB to activate MITF
gene expression [46, 47]. Nicotinic acid hydroxamate
inhibited melanin synthesis through the activation of
the MEK/ERK and AKT/GSK3β signalling pathways in
B16F10 melanoma cells [48]. Dried pomegranate concen-
tration powder exerts whitening effects by effectively
decreasing tyrosinase activity and melanin production in
B16F10 cells through inactivation of the p38 and PKA/
CREB signalling pathways in B16F10 cells [49]. cAMP-
induced PI3K inhibition decreases AKT phosphorylation
and its activation. In the present study, α-MSH-induced
MITF expression was inhibited by K36E and H-89, which is
a PKA inhibitor. In addition, cotreatment with K36E and
H-89 significantly attenuated the K36E-induced reduction
of melanin synthesis. Our results suggested that the antime-
lanogenic activity of K36E is associated with PKA pathway
and thus leads to downregulation of MITF (Fig. 8).
Conclusion
K36E reduced MITF expression by inhibiting CREB
phosphorylation. Additionally, K36E inhibited MITF
expression by upregulating the phosphorylation of AKT
and GSK3β, which subsequently inhibited the expression
of tyrosinase and TRP-1 and thereby reduced melanin
Fig. 8 Schematic diagram showing inhibitory effects of K36E in α-MSH-induced melanogenesis
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biosynthesis. Normal melanocytes and in vivo studies
may be applied for further investigation into the effect
of K36E on melanogenesis. In conclusion, K36E may be
a candidate for the regulation of melanogenesis and it
is likely to have various applications in skin whitening
products in the future.
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